Literature DB >> 21551944

Proteomic analysis of rat brains in a model of neuropathic pain following exposure to electroconvulsive stimulation.

Chihiro Kamagata1, Yosiaki Tsuboko, Tadashi Okabe, Chiyo Sato, Atsuhiro Sakamoto.   

Abstract

Some reports have shown that electroconvulsive shock therapy is effective for treating refractory neuropathic pain. However, its mechanism of action remains unknown. This study analyzes changes in protein expression in the brainstems of neuropathic pain model rats with or without electroconvulsive stimulation (ECS). A neuropathic pain model rat is produced by chronic constrictive injury (CCI) of the sciatic nerve. An ECS was administered to rodents once daily for 6 days after the CCI operation. After ECS, the latency to withdrawal from thermal stimulation was significantly increased. The expression of several proteins was changed after CCI. Ten proteins that increased after CCI then had decreased expression levels (close to control) after ECS, and 8 proteins that decreased after CCI then had increased expression levels (close to control) after ECS. In conclusion, ECS improved thermal hypersensitivity in a rat CCI model. Proteomic analysis showed that altered expression levels of proteins in the brainstem of CCI model rats returned to close to control levels after ECS, including many proteins associated with pain. This trend suggests an association of ECS with improved hypersensitivity, and these results may help elucidate the mechanism of this effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551944     DOI: 10.2220/biomedres.32.91

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  1 in total

1.  Proteomic Identification of an Upregulated Isoform of Annexin A3 in the Spinal Cords of Rats in a Neuropathic Pain Model.

Authors:  Wangyuan Zou; Wei Xu; Zongbin Song; Tao Zhong; Yingqi Weng; Changsheng Huang; Maoyu Li; Chuanlei Zhang; Xianquan Zhan; Qulian Guo
Journal:  Front Neurosci       Date:  2017-09-05       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.